|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12345678910111213...4950» |
- | Trial completion: Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=2000, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed
- | VRC-HIVDNA016-00-VP / National Institute of Allergy and Infectious Diseases
Trial completion, Viral vector: "Prime-Boost" Vaccine Schedule for Prevention of HIV Infection (clinicaltrials.gov) - Jun 30, 2017
P1, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Viral vector: HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers (clinicaltrials.gov) - Jun 30, 2017
P1, N=32, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | leflunomide / Generic mfg.
Trial completion: Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients (clinicaltrials.gov) - Jun 30, 2017
P1, N=41, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | VRC-HIVDNA016-00-VP / National Institute of Allergy and Infectious Diseases
Trial completion: Candidate HIV Vaccine (clinicaltrials.gov) - Jun 30, 2017
P1, N=15, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Viral vector: Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers (clinicaltrials.gov) - Jun 30, 2017
P1, N=36, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Daclizumab to Treat HIV-Infected Patients (clinicaltrials.gov) - Jun 30, 2017
P1, N=10, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Screening HIV-Infected Patients for Vaccine Studies (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=1000, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Invirase (saquinavir) / Roche, Crixivan (indinavir sulfate) / Merck (MSD)
Trial completion: Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers (clinicaltrials.gov) - Jun 30, 2017
P4, N=81, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=56, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection (clinicaltrials.gov) - Jun 30, 2017
P1, N=42, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Phase classification: Effect of Antacids on the Pharmacokinetics of Raltegravir (clinicaltrials.gov) - Jun 28, 2017
P1, N=17, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Phase classification: P=N/A --> P1
- | Trial completion, Trial initiation date, Trial primary completion date: SSAT041: The Pharmacology/Aging Clinic (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=75, Completed, Sponsor: St Stephens Aids Trust
Phase classification: P=N/A --> P1 Recruiting --> Completed | Initiation date: Jan 2011 --> Apr 2011 | Trial primary completion date: Jan 2013 --> Jun 2013
- | Trial completion, Trial primary completion date, Adherence: Managing Medications (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=349, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Initiation date: Jan 2011 --> Apr 2011 | Trial primary completion date: Jan 2013 --> Jun 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Dec 2009
- | Isentress (raltegravir) / Merck (MSD)
Enrollment change, Trial termination, Combination therapy: Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals (clinicaltrials.gov) - Jun 26, 2017
P4, N=6, Terminated, Sponsor: George Washington University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2008 --> Dec 2009 N=80 --> 6 | Completed --> Terminated; no patients completed
- ||||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Combination therapy: FLAMINGO: Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (clinicaltrials.gov) - Jun 20, 2017
P3, N=488, Completed, Sponsor: ViiV Healthcare
N=80 --> 6 | Completed --> Terminated; no patients completed Active, not recruiting --> Completed
- ||||| Trial initiation date: PRINCE1: PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (clinicaltrials.gov) - Jun 19, 2017
P3, N=82, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Initiation date: Nov 2011 --> Oct 2010
- | mupirocin / Generic mfg.
Trial primary completion date: Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=550, Active, not recruiting, Sponsor: Uniformed Services University of the Health Sciences
Initiation date: Nov 2011 --> Oct 2010 Trial primary completion date: Dec 2016 --> May 2017
- ||||||| Trial completion: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - Jun 14, 2017
P3, N=167, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> May 2017 Active, not recruiting --> Completed
- | Trial completion: MRSA-2: Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=52, Completed, Sponsor: Uniformed Services University of the Health Sciences
Active, not recruiting --> Completed Suspended --> Completed
- Vocabria (cabotegravir oral) / ViiV Healthcare
Phase classification, Monotherapy: Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929) (clinicaltrials.gov) - Jun 12, 2017
P2a, N=9, Completed, Sponsor: ViiV Healthcare
Suspended --> Completed Phase classification: P2 --> P2a
- | fosamprenavir / Generic mfg.
Phase classification: Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) - Jun 9, 2017
P3b/4, N=312, Completed, Sponsor: ViiV Healthcare
Phase classification: P2 --> P2a Phase classification: P3 --> P3b/4
- |||| fosamprenavir / Generic mfg.
Trial completion: Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) - Jun 8, 2017
P3b/4, N=312, Completed, Sponsor: ViiV Healthcare
Phase classification: P3 --> P3b/4 No longer recruiting --> Completed
- | tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults (clinicaltrials.gov) - Jun 7, 2017
P2, N=50, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed N=63 --> 50
- | tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults (clinicaltrials.gov) - Jun 6, 2017
P2, N=50, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=63 --> 50 Recruiting --> Completed
- | valacyclovir / Generic mfg.
Trial primary completion date: Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? (clinicaltrials.gov) - Jun 5, 2017
P3, N=202, Active, not recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Aug 2017
- | ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2017 --> Aug 2017 Active, not recruiting --> Completed
- | Trial termination, Trial primary completion date: Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials (clinicaltrials.gov) - Jun 1, 2017
P=N/A, N=488, Terminated, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2016; stopped prematurely due to the absence of safety signal
- fosamprenavir / Generic mfg.
Phase classification, Combination therapy: Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) (clinicaltrials.gov) - May 30, 2017
P3b/4, N=20, Completed, Sponsor: ViiV Healthcare
Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2016; stopped prematurely due to the absence of safety signal Phase classification: P3 --> P3b/4
- | Trial completion, Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=9, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P3 --> P3b/4 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- Trial completion: A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV (clinicaltrials.gov) - May 23, 2017
P4, N=0, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 No longer recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date, Adherence: Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women (clinicaltrials.gov) - May 23, 2017
P=N/A, N=7, Completed, Sponsor: The University of Texas Health Science Center, Houston
No longer recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 7 | Trial primary completion date: Dec 2015 --> Aug 2015
- | Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Trial initiation date, Trial primary completion date: IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (clinicaltrials.gov) - May 12, 2017
P3, N=17, Completed, Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Active, not recruiting --> Completed | N=40 --> 7 | Trial primary completion date: Dec 2015 --> Aug 2015 Initiation date: Jul 2010 --> Oct 2010 | Trial primary completion date: Jul 2011 --> Nov 2010
- | rifampicin / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Trial primary completion date: Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB (clinicaltrials.gov) - May 11, 2017
P4, N=96, Completed, Sponsor: Drugs for Neglected Diseases
Initiation date: Jul 2010 --> Oct 2010 | Trial primary completion date: Jul 2011 --> Nov 2010 Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2016
- | Trial completion: Screening, Brief Intervention, and Referral to Treatment for Offenders (clinicaltrials.gov) - May 10, 2017
P=N/A, N=800, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Dec 2016 Active, not recruiting --> Completed
- GSK2838232 / GSK
Trial termination: A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects (clinicaltrials.gov) - May 9, 2017
P1, N=24, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Completed --> Terminated
- || Trial primary completion date, IO biomarker: The VMVN Study: Virological Monitoring in Viet Nam (clinicaltrials.gov) - May 4, 2017
P=N/A, N=650, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Completed --> Terminated Trial primary completion date: Apr 2017 --> Apr 2019
- AGS-004 / CoImmune
Phase classification: A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 (clinicaltrials.gov) - May 3, 2017
P1, N=6, Completed, Sponsor: Cynthia L Gay, MD
Trial primary completion date: Apr 2017 --> Apr 2019 Phase classification: P1/2 --> P1
- | Intelence (etravirine) / J&J
Trial completion: KALYINTE: A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects (clinicaltrials.gov) - May 1, 2017
P4, N=30, Completed, Sponsor: Therapeutic Concepts
Phase classification: P1/2 --> P1 Recruiting --> Completed
- | zoledronic acid / Generic mfg.
Trial completion: Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (clinicaltrials.gov) - Apr 27, 2017
P2, N=63, Completed, Sponsor: Emory University
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date, Adherence: Improving Antiretroviral Medication Adherence Among HIV-infected Youth (clinicaltrials.gov) - Apr 16, 2017
P2, N=17, Completed, Sponsor: Fenway Community Health
Active, not recruiting --> Completed Recruiting --> Completed | N=40 --> 17 | Trial primary completion date: Apr 2012 --> Jan 2013
- | Trial completion, Enrollment change, Adherence: Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I (clinicaltrials.gov) - Apr 16, 2017
P1, N=31, Completed, Sponsor: Fenway Community Health
Recruiting --> Completed | N=40 --> 17 | Trial primary completion date: Apr 2012 --> Jan 2013 Active, not recruiting --> Completed | N=40 --> 31
- ||| valacyclovir / Generic mfg.
Enrollment change: A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX (clinicaltrials.gov) - Apr 14, 2017
P4, N=384, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=40 --> 31 N=315 --> 384
- | Trial completion, Trial primary completion date, Drug adherence, Adherence: RATA: Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=330, Completed, Sponsor: RAND
N=315 --> 384 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016
- | nevirapine / Generic mfg.
Trial completion: Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV (clinicaltrials.gov) - Apr 13, 2017
P2, N=452, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016 Active, not recruiting --> Completed
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Trial primary completion date: PHI04: Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (clinicaltrials.gov) - Apr 11, 2017
P3, N=33, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2016
- | Phase classification: Treatment Advocacy Intervention for HIV-Positive African Americans (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=216, Completed, Sponsor: Boston Children’s Hospital
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Apr 2016 Phase classification: P2 --> P=N/A
- | Enrollment closed: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Apr 11, 2017
P2, N=9, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P2 --> P=N/A Recruiting --> Active, not recruiting
- | Victrelis (boceprevir) / Roche, Merck (MSD)
Phase classification: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (clinicaltrials.gov) - Apr 7, 2017
P2b, N=99, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Phase classification: P2 --> P2b